# Drugs

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/drugs/

## Facts

| Field | Value |
| --- | --- |
| APC (USD) | 5,290 |
| Citations | 478,988 |
| h-index | 261 |
| Homepage | http://adisonline.com/drugs/pages/default.aspx |
| Open Access | false |
| ISSN-L | 0012-6667 |
| ISSNs | 0012-6667,1179-1950 |
| OpenAlex ID | https://openalex.org/S4436492 |
| Publisher | Adis, Springer Healthcare |
| Works | 10,112 |

## Journal papers

Showing 12 of 38.

- [Herb-Drug Interactions](https://scholariq.org/papers/herb-drug-interactions/)
- [Identification and Assessment of Adherence-Enhancing Interventions in Studies Assessing Medication Adherence Through Electronically Compiled Drug Dosing Histories: A Systematic Literature Review and Meta-Analysis](https://scholariq.org/papers/identification-and-assessment-of-adherence-enhancing-interventions-in-studies/)
- [Golodirsen: First Approval](https://scholariq.org/papers/golodirsen-first-approval/)
- [Clinical Pharmacology and Therapeutic Potential of Artemisinin and its Derivatives in the Treatment of Malaria](https://scholariq.org/papers/clinical-pharmacology-and-therapeutic-potential-of-artemisinin-and-its/)
- [Sotorasib: First Approval](https://scholariq.org/papers/sotorasib-first-approval/)
- [Dehydroepiandrosterone (DHEA): Hypes and Hopes](https://scholariq.org/papers/dehydroepiandrosterone-dhea-hypes-and-hopes/)
- [Baloxavir: First Global Approval](https://scholariq.org/papers/baloxavir-first-global-approval/)
- [Pyrotinib: First Global Approval](https://scholariq.org/papers/pyrotinib-first-global-approval/)
- [Abatacept: A Review in Rheumatoid Arthritis](https://scholariq.org/papers/abatacept-a-review-in-rheumatoid-arthritis/)
- [Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer](https://scholariq.org/papers/cellular-redox-pathways-as-a-therapeutic-target-in-the-treatment-of-cancer/)
- [ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3–5: A Network Meta-Analysis of Randomised Clinical Trials](https://scholariq.org/papers/ace-inhibitor-benefit-to-kidney-and-cardiovascular-outcomes-for-patients-with/)
- [Efgartigimod: First Approval](https://scholariq.org/papers/efgartigimod-first-approval/)

## Journal top topics

Showing 8 of 25.

- [Antibiotics Pharmacokinetics and Efficacy](https://scholariq.org/topics/antibiotics-pharmacokinetics-and-efficacy/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Antibiotic Resistance in Bacteria](https://scholariq.org/topics/antibiotic-resistance-in-bacteria/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Pneumonia and Respiratory Infections](https://scholariq.org/topics/pneumonia-and-respiratory-infections/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Inflammatory mediators and NSAID effects](https://scholariq.org/topics/inflammatory-mediators-and-nsaid-effects/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.